References
[1] Han Y, Yang H, The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol 2019; 2020: 1–6.
[2] Genovese G, Moltrasio C, Berti E, Marzano AV. Skin manifestations associated with COVID-19: Current knowledge and future perspectives. Dermatology 2021;237:1-12.
[3] Feldmeyer L , Heidemeyer K, Yawalkar N. Acute Generalized Pustulosis: Pathogenesis, Genetic Background, Clinical variants and Therapy. Int J Mol Sci 2016;17:1214.
[4] Litaiem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F: Acute generalized exanthematous pustulosis after COVID‐19 treatment with hydroxychloroquine. Dermatol Ther 2020, 33:1-2.
[5] Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther 2020;e13380.
[6] Alzahrani MJ, Moussa MM, Alfaraj D. Acute Generalized Exanthematous Pustulosis after COVID-19 infection: A case report from Saudi Arabia. Cureus 2020; 12:e11609.
[7] Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman. J Eur Acad Dermatol Venereol 2020;34:e457-e459.
[8] Delalau J, Deniau B, Battistella M, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. J Aller Clin Immunol Pract 2020;8(8):2777-2779.e1.
[9] Enos T, Jeong HS, Vandergriff T, Jacobe HT, Chong BF. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. Dermatol Ther 2020;15:e13834.
[10] Torres-Navarro I, Abril-Pérez C, Roca-Ginés J, Sánchez-Arráez J, Botella-Estrada R. A case of cefditoren-induced acute generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions (SCARs) are an issue. J Eur Acad Dermatol Venereol 2020;34:e537-e539.
[11] Haraszti S, Sendil S, Jensen N. Delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with with COVID-19 without the use of hydroxychloroquine. Am J Case Rep 2020;21:e926901.
[12] Ayatollahi A, Robati RM, Kamyab K, Firooz A. Late-onset AGEP-like skin pustular eruption following COVID-19: A possible association. Dermatol Th 2020;33:e14275.
[13] Pezzarossa E, Ungari M, Caresana G, Sagradi F, Cimardi L, et al. Acute generalized Exanthematous Pustulosis (AGEP) in 12 patients treated for SARS-CoV-2 Positive pneumonia. Am J Dermatopathol 2021; Ahead of Print. doi: 10.1097/DAD.0000000000001819.
[14] Skroza N, Bernardini N, Balduzzi V, et al. A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect? J Eur Acad Dermatol Venereol 2020;34:e438-e439.
[15] Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:10331034.